Pergamon

Bioorganic & Medicinal Chemistry Letters 10 (2000) 1001

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Corrigendum

Corrigendum to "2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors"†

(*Bioorg. Med. Chem. Lett.* **1999**, *9*, 91–96)

Patricia Imbach,[a,*] Hans-Georg Capraro,[a] Pascal Furet,[a,b] Helmut Mett,[a] Thomas Meyer[a] and Jürg Zimmermann[a]

[a]*Oncology Research, Novartis Pharmaceuticals, Therapeutic Area Oncology, Novartis Limited, CH-4002 Basel, Switzerland*
[b]*Molecular Modelling, Novartis Pharmaceuticals, Therapeutic Area Oncology, Novartis Limited, CH-4002 Basel, Switzerland*

On page 93, Table 1, R_2 is not correct for some of the examples (5–11). The correct text should read:

Table 1. Optimization of 2,6,9-trisubstituted purine derivatives



Compd no.	R_1	R_2	CDK1[h] IC_{50} (μM)	T24[i] IC_{50} (μM)	FAB-MS $(M+H)^+$	mp (°C)
5	3-Cl	$-NHCH_2CH_2OH$	0.33	17.5	333	99–102
6	3-Cl	$-NHCH_2CH_2NH_2$	0.08	3.16	332	103
7[a]	4-F	$-NHCH_2CH_2NH_2$	0.45	8.3	316	>250
8[a]	3-CN	$-NHCH_2CH_2NH_2$	0.56	5.24	323	>175 dec.
9	3-OCH_3	$-NHCH_2CH_2NH_2$	0.55	9.9	328	Oil
10[a]	3-CF_3	$-NHCH_2CH_2NH_2$	0.7	6.08	366	>250 dec.
11[a]	3-F	$-NHCH_2CH_2NH_2$	0.60	6.5	316	>250 dec.

*Corresponding author. Tel.: +4161-696-6256; fax: +4161-696-6246; e-mail: patricia.imbach@pharma.novartis.com
†PII of original article: S0960-894X(98)00691-X.

PII: S0960-894X(00)00119-0